More Noxopharm Ltd. news
Noxopharm Ltd.ASX: NOX

Approval to be sought for COVID-19 Clinical Study in U.S.

Apr 20, 2020 at 10:38 PM EDT · Issued by Noxopharm Ltd.

Filed with ASX · Apr 20, 2020 at 10:38 PM EDT · 5 pages · English

On 6ix: 6ix.com/news/approval-to-be-sought-for-covid-19-clinical-study-in-us

Noxopharm Ltd. on 6ix

Story so far

  • DARRT-1 Clinical Data WebinarDec 20, 2019
  • Further Review Shows Major Clinical Benefits from VeyondaSep 30, 2019
  • Pre-Clinical Evidence Confirms Veyonda Abscopal EffectAug 21, 2019

Earlier from Noxopharm

  • Noxopharm Investigating Potential COVID-19 TreatmentMar 31, 2020
  • Veyonda Awarded First Allowed Patent ApplicationMar 16, 2020
  • LuPIN Prostate Cancer Trial Fully RecruitedMar 2, 2020
  • Half Year Accounts and Chairman LetterFeb 25, 2020
  • FDA grants IND approval to VeyondaFeb 20, 2020

Later from Noxopharm

  • Pipeline Expands With Potential New Brain Cancer TreatmentApr 22, 2020
  • Abscopal Responses Achieved in Prostate CancerApr 29, 2020
  • Noxopharm March 2020 Quarterly Report & Appendix 4CApr 30, 2020
  • $7.9 Million Fully Underwritten Entitlement Offer AnnouncedMay 12, 2020
  • Entitlement Offer ProspectusMay 13, 2020
All Noxopharm news releases↗

Follow Noxopharm into a list and get an email when it puts out news.

Follow Noxopharm
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer